# Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment

> **NCT06751914** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Nanchang University** · enrollment: 10 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)

## Interventions

- **COMBINATION_PRODUCT:** Conventional second-line therapy
- **DRUG:** Neoantigen-based peptide vaccine

## Key facts

- **NCT ID:** NCT06751914
- **Lead sponsor:** The First Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751914, "Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06751914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*